European Archives of Psychiatry and Clinical Neuroscience
June 11, 2024
N. Treves, N. Yakirevich-Amir, W. Abu Ahmad et al.
There is a potential link between cannabis and mental disorders. Cannabis exposure involves in many cases negative mental emotions, which are unpleasant sensations or thoughts. Whereas mild cases of negative mental emotions inflict patient’s quality of life, more severe cases lead to therapy discontinuations, or even hospitalizations and death. This study characterizes cannabis users who...
JAMA Health Forum
June 7, 2024
Kevin H. Yang, Nora Satybaldiyeva, Matthew R Allen et al.
16 citations
Despite growing interest in psychedelics, there is a lack of routine population-based surveillance of psychedelic microdosing (taking "subperceptual" doses of psychedelics, approximately one-twentieth to one-fifth of a full dose, over prolonged periods). Analyzing Google search queries can provide insights into public interest and help address this gap. To analyze trends in public interest in...
Addiction
June 6, 2024
Wayne Hall, Keith Humphreys, John Marsden et al.
18 citations
Abstract The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action...
Behavioural Pharmacology
June 1, 2024
Lawrence M Carey, Saba Ghodrati, Charles P France
Cannabis is a pharmacologically complex plant consisting of hundreds of potentially active compounds. One class of compounds present in cannabis that has received little attention are terpenes. Traditionally thought to impart aroma and flavor to cannabis, it has become increasingly recognized that terpenes might exert therapeutic effects themselves. Several recent reports have also indicated...
Neuropsychopharmacology
June 1, 2024
Conor H. Murray, Joel Frohlich, Connor J Haggarty et al.
30 citations
Neural complexity correlates with one's level of consciousness. During coma, anesthesia, and sleep, complexity is reduced. During altered states, including after lysergic acid diethylamide (LSD), complexity is increased. In the present analysis, we examined whether low doses of LSD (13 and 26 µg) were sufficient to increase neural complexity in the absence of altered states of consciousness. In...
Journal of Cannabis Research
May 31, 2024
S Zhao, Bruna Brands, Pamela Kaduri et al.
13 citations
Cannabis has been shown to impact driving due to changes produced by delta-9-tetrahydrocannabinol (THC), the psychoactive component of cannabis. Current legal thresholds for blood THC while driving are based predominantly on evidence utilizing smoked cannabis. It is known that levels of THC in blood are lower after eating cannabis as compared to smoking yet the impact of edibles on driving and...
Neuropsychopharmacology
May 28, 2024
Natalie Ertl, Tom P. Freeman, Claire Mokrysz et al.
19 citations
Adolescence is a time of rapid neurodevelopment and the endocannabinoid system is particularly prone to change during this time. Cannabis is a commonly used drug with a particularly high prevalence of use among adolescents. The two predominant phytocannabinoids are Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which affect the endocannabinoid system. It is unknown whether this...
Schizophrenia Research: Cognition
May 11, 2024
Christopher Dawes, Samuel Joy McGreal, Shivika Marwaha et al.
Aberrant attentional salience has been implicated in the cannabis-psychosis association. Here, history and frequency of cannabis use were examined against changes in overshadowing (OS), a cue competition paradigm that involves salience processing. Additionally, we examined the association between OS and alternative measures of aberrant salience, as well as schizotypy, in a non-clinical adult...
Psychological Medicine
May 9, 2024
J. Selten, Marta Di Forti, Diego Quattrone et al.
BACKGROUND We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. METHODS We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of...
Journal of Cannabis Research
May 3, 2024
Cristian Caprari, Elena Ferri, M. Vandelli et al.
Since its discovery as one of the main components of cannabis and its affinity towards the cannabinoid receptor CB1, serving as a means to exert its psychoactivity, Δ^9-tetrahydrocannabinol (Δ^9-THC) has inspired medicinal chemists throughout history to create more potent derivatives. Initially, the goal was to synthesize chemical probes for investigating the molecular mechanisms behind the...